SCHEMBL614596

SCHEMBL614596

CC1CC(c2ccc(O)cc2O)CCO1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.38
GAA P10253 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
PTGS1 P23219 1/20 0.37
PTGS2 P35354 1/20 0.37
CYP19A1 P11511 1/20 0.37
TYR P14679 1/20 0.37
CHRNB2 P17787 1/20 0.36
CHRNA4 P43681 1/20 0.36
NPC1 O15118 2/20 0.35
KDM4E B2RXH2 1/20 0.35
USP2 O75604 1/20 0.35
LMNA P02545 1/20 0.35
TP53 P04637 1/20 0.35
MAPT P10636 1/20 0.35
PKM P14618 1/20 0.35
HPGD P15428 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL614595 1.00 ALDH1A1 (0.38) ALDH1A1GAASMN1; SMN2MEN1KMT2A
SCHEMBL614972 1.00 ALDH1A1 (0.38) ALDH1A1GAASMN1; SMN2MEN1KMT2A
SCHEMBL29000468 0.81 HTR2A (0.39) ALDH1A1GAASMN1; SMN2MEN1KMT2A
SCHEMBL613674 0.81 DRD2 (0.39) DRD2DRD3
SCHEMBL613675 0.81 DRD2 (0.39) DRD2DRD3
SCHEMBL614061 0.81 DRD2 (0.39) DRD2DRD3
SCHEMBL613627 0.80 TYR (0.40) ALDH1A1GAASMN1; SMN2MEN1KMT2A
SCHEMBL613628 0.80 TYR (0.40) ALDH1A1GAASMN1; SMN2MEN1KMT2A
SCHEMBL614173 0.79 ESR1 (0.38) PTGS1PTGS2CYP19A1TYRCHRNB2
SCHEMBL614174 0.79 ESR1 (0.38) PTGS1PTGS2CYP19A1TYRCHRNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016102399-A1 AQUEOUS COMPOSITION COMPRISING A 4-(HETEROCYCLOALKYL)-BENZENE-1,3-DIOL COMPOUND AND A HYDROTROPE L'OREAL (FR) 2016-06-30 WO claimed
WO-2016102400-A1 COMPOSITION COMPRISING A 4-(HETEROCYCLOALKYL)-BENZENE-1,3-DIOL COMPOUND AND A SPECIFIC SOLVENT L'OREAL (FR) 2016-06-30 WO claimed
WO-2016102398-A1 AQUEOUS COMPOSITION COMPRISING A 4-(HETEROCYCLOALKYL)-BENZENE-1,3-DIOL COMPOUND, A POLYMER AND A GLYCOL L'OREAL (FR) 2016-06-30 WO claimed
WO-2016102402-A1 AQUEOUS COMPOSITION COMPRISING A 4-(HETEROCYCLOALKYL)-BENZENE-1,3-DIOL COMPOUND, A C2-C4 MONOALCOHOL, AND A GLYCOL L'OREAL (FR) 2016-06-30 WO claimed
EP-2529735-B1 COMPOSITIONS COMPRISING 4-(HETEROCYCLOALKYL)BENZENE-1,3-DIOL DERIVATIVES WITH TYROSINASE ENZYME INHIBITING ACTIVITY GALDERMA RES & DEV (FR) 2014-06-25 EP claimed
US-8372879-B2 4-(heterocycloalkyl) benzene-1,3-diol compounds as tyrosinase inhibitors, process for the preparation thereof and use thereof in human medicine and also in cosmetics GALDERMA RESEARCH & DEVELOPMENT (FR) 2013-02-12 US claimed
EP-2529735-A1 Novel 4-(heterocycloalkyl)benzene-1,3-diol compounds as tyrosinase inhibitors, process for the preparation thereof and use thereof in human medicine and also in cosmetics Galderma Research & Development (FR) 2012-12-05 EP claimed
EP-2373310-B1 NOVEL 4-(HETEROCYCLOALKYL)BENZENE-1,3-DIOL COMPOUNDS AS TYROSINASE INHIBITORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND ALSO IN COSMETICS GALDERMA RES & DEV (FR) 2012-10-10 EP claimed
US-20120041213-A1 4-(HETEROCYCLOALKYL) BENZENE -1,3-DIOL COMPOUNDS AS TYROSINASE INHIBITORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND ALSO IN COSMETICS GALDERMA RESEARCH & DEVELOPMENT (FR) 2012-02-16 US claimed
EP-2373310-A1 NOVEL 4-(HETEROCYCLOALKYL)BENZENE-1,3-DIOL COMPOUNDS AS TYROSINASE INHIBITORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND ALSO IN COSMETICS Galderma Research & Development (FR) 2011-10-12 EP claimed
WO-2010063773-A1 NOVEL 4-(HETEROCYCLOALKYL)BENZENE-1,3-DIOL COMPOUNDS AS TYROSINASE INHIBITORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND ALSO IN COSMETICS GALDERMA RESEARCH & DEVELOPMENT (FR) 2010-06-10 WO claimed
WO-2016102399-A1 AQUEOUS COMPOSITION COMPRISING A 4-(HETEROCYCLOALKYL)-BENZENE-1,3-DIOL COMPOUND AND A HYDROTROPE L'OREAL (FR) 2016-06-30 WO disclosed
WO-2016102400-A1 COMPOSITION COMPRISING A 4-(HETEROCYCLOALKYL)-BENZENE-1,3-DIOL COMPOUND AND A SPECIFIC SOLVENT L'OREAL (FR) 2016-06-30 WO disclosed
WO-2016102402-A1 AQUEOUS COMPOSITION COMPRISING A 4-(HETEROCYCLOALKYL)-BENZENE-1,3-DIOL COMPOUND, A C2-C4 MONOALCOHOL, AND A GLYCOL L'OREAL (FR) 2016-06-30 WO disclosed
WO-2016102398-A1 AQUEOUS COMPOSITION COMPRISING A 4-(HETEROCYCLOALKYL)-BENZENE-1,3-DIOL COMPOUND, A POLYMER AND A GLYCOL L'OREAL (FR) 2016-06-30 WO disclosed
EP-2529735-A1 Novel 4-(heterocycloalkyl)benzene-1,3-diol compounds as tyrosinase inhibitors, process for the preparation thereof and use thereof in human medicine and also in cosmetics Galderma Research & Development (FR) 2012-12-05 EP disclosed
EP-2373310-B1 NOVEL 4-(HETEROCYCLOALKYL)BENZENE-1,3-DIOL COMPOUNDS AS TYROSINASE INHIBITORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND ALSO IN COSMETICS GALDERMA RES & DEV (FR) 2012-10-10 EP disclosed
US-20120041213-A1 4-(HETEROCYCLOALKYL) BENZENE -1,3-DIOL COMPOUNDS AS TYROSINASE INHIBITORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND ALSO IN COSMETICS GALDERMA RESEARCH & DEVELOPMENT (FR) 2012-02-16 US disclosed
EP-2373310-A1 NOVEL 4-(HETEROCYCLOALKYL)BENZENE-1,3-DIOL COMPOUNDS AS TYROSINASE INHIBITORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND ALSO IN COSMETICS Galderma Research & Development (FR) 2011-10-12 EP disclosed
WO-2010063773-A1 NOVEL 4-(HETEROCYCLOALKYL)BENZENE-1,3-DIOL COMPOUNDS AS TYROSINASE INHIBITORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND ALSO IN COSMETICS GALDERMA RESEARCH & DEVELOPMENT (FR) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120041213-A1 4-(HETEROCYCLOALKYL) BENZENE -1,3-DIOL COMPOUNDS AS TYROSINASE INHIBITORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND ALSO IN COSMETICS TYR, DDT, PAH ALDH1A1 56/4885GAA 49/4885SMN1; SMN2 4045/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.